Long-term remission in an adult heart transplant recipient with advanced Burkitt's lymphoma post-transplant lymphoproliferative disorder after anthracycline-free chemotherapy: A case report and literature review.
Adult
Anthracyclines
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Burkitt Lymphoma
/ complications
Drug Therapy, Combination
Epstein-Barr Virus Infections
/ complications
Female
Heart Transplantation
/ adverse effects
Humans
Lymphoproliferative Disorders
/ diagnosis
Transplant Recipients
Burkitt's lymphoma
anthracycline sparing
heart transplant
post-transplant lymphoproliferative disorder
Journal
Transplant infectious disease : an official journal of the Transplantation Society
ISSN: 1399-3062
Titre abrégé: Transpl Infect Dis
Pays: Denmark
ID NLM: 100883688
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
received:
28
05
2019
revised:
25
01
2020
accepted:
02
02
2020
pubmed:
23
2
2020
medline:
8
6
2021
entrez:
21
2
2020
Statut:
ppublish
Résumé
Incidence of Burkitt's lymphoma post-transplant lymphoproliferative disorder (BL-PTLD) in solid organ transplant (SOT) recipients in 1.4%-1.6% with unknown cure rate. We report a case of Epstein-Barr virus (EBV) positive, late-onset BL-PTLD in a 24-year-old EBV donor positive/recipient negative female. This is the first reported case of advanced BL-PTLD post-heart transplant in an adult. This is also the first reported case of treatment of advanced BL-PTLD in a heart transplant recipient with a combined chemotherapy regimen without anthracyclines to avoid cardiotoxicity. The patient received 6 cycles of R-COEP (rituximab with cyclophosphamide, vincristine, etoposide, prednisone) over 6 months and subsequently 3 cycles of high-dose methotrexate (MTX) over 3 months for CNS prophylaxis. She remains without evidence of disease at 19 months post-treatment. This case demonstrates that an anthracycline-free regimen can be the therapy option for patients with BL-PTLD after heart transplantation.
Substances chimiques
Anthracyclines
0
Types de publication
Case Reports
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13265Informations de copyright
© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Picarsic J, Jaffe R, Mazariegos G, et al. Post-transplant Burkitt lymphoma is a more aggressive and distinct form of post-transplant lymphoproliferative disorder. Cancer. 2011;117(19):4540-4550.
San-Juan R, Comoli P, Caillard S, et al. Epstein-Barr-virus-related post transplant lymphoproliferative disorder in solid organ transplant recipients. Clin Microbiol Infect. 2014;20(suppl 7):109-118.
Morscio J, Tousseyn T. Recent insights in the pathogenesis of post-transplantation lymphoproliferative disorders. World J Transplant. 2016;6(3):505-516.
Preiksaitis J, Keay S. Diagnosis and mangement of posttransplant lymphoproliferative disorder in solid-organ transplant recipients. Clin Infect Dis. 2001;33(1):S38-S46.
Twist C, Castillo R. Treatment of recurrent posttransplant lymphoproliferative disorder of the central nervous system with high-dose methotrexate. Case Rep Transplant. 2013;2013:765230.
Zimmermann H, Reinke P, Neuhaus R, et al. Burkitt post-transplantation lymphoma in adult solid organ transplant recipients. Cancer. 2012;118(19):4715-4724.
Siddhartha G, Vijay P. R-CHOP versus R-CVP in the treatment of follicular lymphoma: a meta-analysis and critical appraisal of current literature. J Hematol Oncol. 2009;2:14.
Yager J, Magaret A, Kuntz S, et al. Valganciclovir for the suppression of epstein-barr virus replication. J Infect Dis. 2017;216(2):198-202.
Gong JZ, Stenzel TT, Bennett ER, et al. Burkitt lymphoma arising in organ transplant recipients: a clinicopathologic study of five cases. Am J Surg Pathol. 2003;27(6):818-827.
Law MF, Chan HN, Leung C, et al. Burkitt-like post-transplant lymphoproliferative disorder (PTLD) presenting with breast mass in a renal transplant recipient: a report of a rare case. Ann Hematol. 2014;93(12):2083-2085.
Dierickx D, Tousseyn T, Gheysens O. How I treat posttransplant lymphoproliferative disorders. Blood. 2015;126:2274-2283.
Naik S, Tayapongsak K, Robbins K, et al. Burkitt’s lymphoma presenting as late-onset posttransplant lymphoproliferative disorder following kidney and pancreas transplantation: case report and review of the literature. Case Rep Oncol. 2013;6(1):6-14.
Kataoka K, Seo S, Sugawara Y, et al. Post-transplant lymphoproliferative disorder after adult-to-adult living donor liver transplant: case series and review of literature. Leuk Lymphoma. 2010;51(80):1494-1501.
Lohrisch CA, Nevill TJ, Barnett MJ, et al. Development of a biologically distinct EBV-related lymphoproliferative disorder following autologous bone marrow transplantation for an EBV-negative post-renal allograft Burkitt's lymphoma. Leuk Lymphoma. 2000;39(1-2):195-201.
Mainardi V, Gerona S, Ardao G, et al. Locally acquired chronic hepatitis e followed by epstein-barr virus reactivation and Burkitt lymphoma as a suspected extrahepatic manifestation in a liver transplant recipient. Am J Case Rep. 2019;20:1016-1021.
Chan TSY, Hwang Y-Y, Gill H, et al. Post-transplant lymphoproliferative diseases in Asian solid organ transplant recipients: late onset and favorable response to treatment. Clin Transplant. 2012;26(5):679-683.